Scarica l'app Stockscreener
14.77
4.59%
-0.71
Dopo l'orario di chiusura:
14.50
-0.27
-1.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.48
Aprire:
$15.16
Volume 24 ore:
3.36M
Relative Volume:
1.52
Capitalizzazione di mercato:
$1.01B
Reddito:
$1.01B
Utile/perdita netta:
$-204.71M
Rapporto P/E:
-4.8125
EPS:
-3.0691
Flusso di cassa netto:
$-29.67M
1 W Prestazione:
-25.67%
1M Prestazione:
-22.99%
6M Prestazione:
-15.70%
1 anno Prestazione:
-35.73%
Intervallo 1D:
$14.18
$15.35
Intervallo di 1 settimana:
$14.18
$20.03
Portata 52W:
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
14.77 | 1.06B | 1.01B | -204.71M | -29.67M | -3.0691 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Aggiornamento | Truist | Hold → Buy |
| 2026-03-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Aggiornamento | Lake Street | Hold → Buy |
| 2026-02-20 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Ripresa | TD Cowen | Buy |
| 2025-12-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Ripresa | Stifel | Hold |
| 2025-09-08 | Iniziato | Oppenheimer | Outperform |
| 2025-08-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Downgrade | Citigroup | Neutral → Sell |
| 2025-06-16 | Iniziato | Truist | Hold |
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
TNDM Q1 Deep Dive: Margin Expansion and Pipeline Advances Amid Business Model Shift - Yahoo! Finance Canada
Tandem Diabetes Care, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:TNDM) 2026-05-11 - Seeking Alpha
Earnings call transcript: Tandem Diabetes Care Q1 2026 sees record sales, stock drops - Investing.com Canada
Truist Financial Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $31 - Moomoo
TNDM Maintained by Barclays -- Price Target Lowered to $55.00 - GuruFocus
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $24 to $50 - Moomoo
Compared to estimates, Tandem Diabetes Care (TNDM) Q1 earnings: A look at key metrics - MSN
Tandem Diabetes Care (TNDM) Nears Break Even In Q4 Losses Challenging Bearish Narratives - Sahm
Tandem Diabetes Care Q1 Earnings Call Highlights - TradingView
Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today - TradingView
Tandem to file tubeless insulin pump with FDA this quarter - MedTech Dive
Mizuho Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Raises Target Price to $24 - Moomoo
Tandem Diabetes Q1 2026 slides: record revenue, profitability returns By Investing.com - Investing.com Australia
TNDM Maintains Financial Forecast for 2026 with Sales Projections - GuruFocus
TNDM Reports Strong Q1 Revenue Growth - GuruFocus
Tandem Diabetes Care Announces First Quarter 2026 Financial Results - BioSpace
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
MSN Money - MSN
Tandem Diabetes Q1 2026 slides: record revenue, profitability returns - Investing.com India
Earnings call transcript: Tandem Diabetes Care Q1 2026 beats EPS forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Tandem Diabetes Care Q1 2026 beats EPS forecast - Investing.com
Tandem Diabetes Care, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Tandem Diabetes Care Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tandem Diabetes Care (NASDAQ:TNDM) Surges 10% After Q1 Beat on Revenue and Earnings - ChartMill
Tandem Diabetes Care : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Compared to Estimates, Tandem Diabetes Care (TNDM) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
TNDM Financials: Income Statement, Balance Sheet & Cash Flow | Tandem Diabetes - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Tandem Diabetes Care (TNDM) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (TNDM) Tandem Diabetes Care, Inc. Reports Q1 Revenue $247.2M, vs. FactSet Est of $240.4M - marketscreener.com
Q1 2026 Tandem Diabetes Care Inc Earnings Call Transcript - GuruFocus
Tandem Diabetes (NASDAQ: TNDM) lifts Q1 2026 margin as loss shrinks sharply - Stock Titan
Tandem Diabetes’s (NASDAQ:TNDM) Q1 CY2026: Beats On Revenue, Stock Jumps 10.9% - Yahoo Finance
Tandem Diabetes Care, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tandem Diabetes shipped 29,000 insulin pumps and kept 2026 targets - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) lifts Q1 2026 margins and reaffirms outlook - Stock Titan
Tandem Diabetes faces earnings test as pay-as-you-go shift weighs By Investing.com - Investing.com Australia
Tandem Diabetes faces earnings test as pay-as-you-go shift weighs - Investing.com Australia
A Look At Tandem Diabetes Care (TNDM) Valuation After FDA Clearance For Pregnancy Use Of Control IQ Plus - Sahm
Tandem Diabetes (TNDM) Q1 Earnings: What To Expect - The Globe and Mail
Tandem Diabetes Care upgraded by Robert W. Baird with a new price target - Quantisnow
Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032 - Quantisnow
Is FDA Pregnancy Clearance For Control-IQ+ Reshaping The Investment Case For Tandem Diabetes Care (TNDM)? - Sahm
Voya Financial (NYSE: VOYA) discloses 6.3% stake in Tandem Diabetes Care (TNDM) - Stock Titan
FDA Approves Automated Insulin Delivery System for Pregnancy in Type 1 Diabetes - Medical Dialogues
Price-Driven Insight from (TNDM) for Rule-Based Strategy - Stock Traders Daily
How Investors Are Reacting To Tandem Diabetes Care (TNDM) Expanding Control-IQ+ Use To Type 1 Pregnancies - Yahoo Finance
FDA flags high-risk recall for Tandem Diabetes Mobi pumps - MSN
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):